EZ Traders Forum

[ToshacH]

I like it too, small o/s .09 x .13 market cap of 500k

NOVA BIOGENETICS INC The company had 5,617,978 shares issued and outstanding of the Common Stock
issued as of November 30, 2003.


Nova BioGenetics Sub-Registers Anabec Inc., Kor-Chem, Inc., and WorldCHEM

2003-12-19 10:57 ET - News Release

ATLANTA -- (Business Wire) -- Dec. 19, 2003

Nova BioGenetics (OTC Bulletin Board: NVBG) announces it
has sub-registered ANABEC Inc., Kor-Chem, Inc., and WorldCHEM products
with the US EPA.
Anabec's product removes stronger categories of mold and bacteria
from porous building materials that harbor these strains, addressing
the Indoor Air Quality issue. No longer are owners confined to the old
protocol which dictated that this matter be removed, an ineffective
and costly method. Now materials can actually be "cleaned" and
"sealed" with Anabec's patented dyne penetrating surfactant used with
an EPA registered antimicrobial shield.
Primarily targeting the industrial and institutional markets,
Kor-Chem, Inc. is a specialty chemicals manufacturer of a broad range
of products from intermediates and concentrates to solvent based and
aqueous fluids in liquid, solid, and granulated grade form. Their
43,000 sq. ft. facility houses production, packaging, and warehousing.
Stainless steel reactors/mixing vessels make a wide range of products.
Kor-Chem's plant also handles a wide range of viscosities from low
viscosity fluid to high viscosity pastes and is configured to safely
use solvents, acids, and alkalis.
A chemical manufacturer of commercial cleaning supplies,
WorldCHEM, Inc. has devised a "Comprehensive Disease and Odor Control
Program." Their products range from EPA registered disinfectants to
industrial concentrates, RTU and antimicrobial cleaning compounds.
Additionally, WorldCHEM manufactures a complete line of floor care
products and offers a "One-Stop" shopping concept to all their
customers. WorldCHEM takes pride in their Quality Assurance Program
which has earned them a rating of "Excellent" from their National
Account Customers.

About Nova BioGenetics:

Nova BioGenetics Inc., ("Nova"), is a biopharmaceuticals company
headquartered in Atlanta, Georgia. Nova is engaged in the discovery,
development, and commercialization of new therapeutic agents that
treat life-threatening infectious diseases. Nova BioGenetics'
pipeline, for both FDA and EPA regulatory agencies, is based on
patented technology and Nova's own initial bench studies used as a
broad base for applications with existing antibiotic compounds.
Attaching the patented technology with antibiotic compounds has proven
to facilitate potential disruption of bacterial agents thus producing
new therapeutic agents to be marketed.
Nova also operates a division responsible for the sale of
cutting-edge patented and EPA approved antimicrobials and biocides.
For more information on Nova and its product line, please visit
http://www.novabiogenetics.com , Ph.# 770-650-6508, Fax #
770-650-0411. For investor information, contact Todd Smith, Dir. of
Investor Relations.
Contacts:

Nova BioGenetics Inc., Atlanta
Investor Relations
Todd Smith, 770-650-6508